- Home
- A-Z Publications
- Current Pharmaceutical Design
- Previous Issues
- Volume 22, Issue 41, 2016
Current Pharmaceutical Design - Volume 22, Issue 41, 2016
Volume 22, Issue 41, 2016
-
-
Therapeutic Potential of Targeting TREM-1 in Inflammatory Diseases and Cancer
Authors: Maria Carla Bosco, Federica Raggi and Luigi VaresioThe triggering receptor expressed on myeloid cells (TREM)-1 is a member of the Ig-like immunoregulatory receptor family and a major amplifier of innate immune responses. TREM- 1 has been implicated in the development and perpetuation of a number of inflammatory disorders, and soluble TREM-1 levels are a clinically valuable diagnostic and prognostic biomarker in patients with sepsis and other types of acute and chronic i Read More
-
-
-
Understanding Tumor-Antigen Presentation in the New Era of Cancer Immunotherapy
Authors: Daniela Cerezo-Wallis and Maria S. SoengasFor more than a century, scientists have tried to exploit the anti-tumoral potential of the immune system to treat cancer. However, clinical success was traditionally limited. Consequently, classical anti-neoplastic treatments such as surgery, radiotherapy, and chemotherapy used to be the first line of treatment. Fortunately, this scenario is changing, particularly with the identification of immune checkpoint inhibitors. Now more t Read More
-
-
-
Role of Salmonella Typhi Vi Antigen and Secretory Systems on Immune Response
Authors: Ermin Schadich, Petr Dzubak and Marian HajduchVirulence capsular polysaccharide (Vi antigen) and Salmonella`s Pathogenicity Island type 1 and 2 TTSS (SPI-1 and SPI-2 TTSS) are important membrane virulence factors of human restricted pathogen S. Typhi. The Vi antigen modulates different proinflammatory signaling pathways in infected macrophages, microfold epithelial and dendritic cells. SPI-2 TTSS and its effectors are required for promoting bacterial intracell Read More
-
-
-
Allergic Asthma: A Summary from Genetic Basis, Mouse Studies, to Diagnosis and Treatment
Authors: Cynthia Kanagaratham and Danuta RadziochAsthma is an allergic disease that affects approximately 300 million people worldwide. Two of its phenotypes routinely assessed at the clinic include airway hyperresponsiveness and IgE production. They can be measured in a non-invasive manner and have been used for genetic studies. The genetic complexity of asthma and its phenotypes makes it difficult to map their genetic contributors. Human studies require large sampl Read More
-
-
-
Asthma COPD Overlap Syndrome: An Approach to A Real -World Endotype in Obstructive Lung Disease?
Authors: Maria Laucho-Contreras, Maria Montes de Oca and Caroline A. OwenBackground: Although some patients with obstructive lung disease (OLD) have features of both asthma and chronic obstructive pulmonary disease (COPD), the term "asthma-COPD overlap syndrome (ACOS)" was coined only relatively recently. However, there are gaps in our knowledge of the clinical features, pathogenesis, prognosis, and management of ACOS patients. Objectives: To review the literature on ACOS to determin Read More
-
-
-
New Biological Insights in the Immunomodulatory Effects of Mucosal Polybacterial Vaccines in Clinical Practice
A main focus in healthcare is the active search for alternative strategies to antibiotics, both for prophylactic and therapeutical interventions, due to the accelerated and widespread increase in antibiotic resistance. This problem is more marked for patients with recurrent infections, in which the risk for antibiotic resistance and adverse effects is higher and can be life-threatening. Although antibiotics remain the mainstay of treat Read More
-
-
-
An Updated Review of ISCOMSTM and ISCOMATRIXTM Vaccines
Authors: Alexis Garcia and Diego LemaThe need for the improvement of vaccine potency as well as reducing toxicity in healthy recipients has motivated studies of the formulation of vaccines regarding control of how, when, and where antigens and adjuvants encounter immune cells and other cells/tissues following vaccine administration. Immunostimulatory complexes (ISCOMs) and ISCOMATRIXTM adjuvants are versatile and flexible systems with various p Read More
-
-
-
Subcutaneous Immunoglobulins: A Promising Alternative for Immunomodulation?
More LessCumulative recent evidence from clinical trials, observational studies and case reports has shown that subcutaneous administration of immunoglobulin (SCIg) exerts similar immunomodulatory capacity than intravenous immunoglobulin (IVIg) in autoimmune neurological diseases. Besides the beneficial clinical effects, the profile of safety and autonomy for the patient is higher for SCIg, while it is cost-saving in terms Read More
-
-
-
A Review of Clinical Trials of Belimumab in the Management of Systemic Lupus Erythematosus
Authors: Alexis Garcia and Juan B. De SanctisThere have been few changes over the last 50 years in the treatment of Systemic lupus erythematosus (SLE), using non-specific anti-inflammatory agents such as: nonsteroidal anti-inflammatory drugs along with the immune cell modulating agent hydroxychloroquine for mild disease, and broad spectrum immunosuppressants plus antiinflammatories such as corticosteroids, azathioprine, cyclophosphamide, or mycophenolate duri Read More
-
-
-
A New Direction in Ophthalmic Development: Nanoparticle Drug Delivery Systems
More LessThe purpose of each dosage form is to provide an optimal therapeutic effect with a minimum dose and with minimal side effects. This is particularly relevant for drugs that require systemic administration, higher dosing and/or show lower bioavailability. Тhe eye as an anatomical structure is an extremely protected organ. In this regard, providing an optimal bioavailability in the eye tissues, resulting in the desired therapeutic effe Read More
-
-
-
The Influence of Tetracycline Inducible Targeting Rat PPARγ Gene Silencing on the Osteogenic and Adipogenic Differentiation of Bone Marrow Stromal Cells
Authors: Xiaobo Feng, Xianzhe Liu, Xianyi Cai, Tao Lin, Weihua Xu, Cao Yang, Yongwei Liu, Shuhua Yang and Dehao FuPeroxisome proliferator-activated receptor γ (PPARγ) has been considered as the master regulator for adipogenesis of bone marrow stromal cells (BMSCs). However, there are few reports regarding the effect of PPARγ gene silencing on osteogenic and adipogenic differentiation in rat BMSCs, and no reports about tissue targeting and conditional knockdown of PPARγ gene. In this study, we construct rat PPARγ gene shRNA Tet-o Read More
-
Volumes & issues
-
Volume 31 (2025)
-
Volume 30 (2024)
-
Volume 29 (2023)
-
Volume 28 (2022)
-
Volume 27 (2021)
-
Volume 26 (2020)
-
Volume 25 (2019)
-
Volume 24 (2018)
-
Volume 23 (2017)
-
Volume 22 (2016)
- Issue 46
- Issue 45
- Issue 44
- Issue 43
- Issue 41
- Issue 42
- Issue 40
- Issue 39
- Issue 38
- Issue 37
- Issue 36
- Issue 35
- Issue 34
- Issue 32
- Issue 31
- Issue 30
- Issue 29
- Issue 28
- Issue 27
- Issue 26
- Issue 25
- Issue 24
- Issue 23
- Issue 22
- Issue 21
- Issue 20
- Issue 19
- Issue 18
- Issue 17
- Issue 16
- Issue 15
- Issue 14
- Issue 13
- Issue 12
- Issue 11
- Issue 10
- Issue 9
- Issue 8
- Issue 7
- Issue 6
- Issue 5
- Issue 4
- Issue 33
- Issue 3
- Issue 2
- Issue 1
-
Volume 21 (2015)
-
Volume 20 (2014)
-
Volume 19 (2013)
-
Volume 18 (2012)
-
Volume 17 (2011)
-
Volume 16 (2010)
-
Volume 15 (2009)
-
Volume 14 (2008)
-
Volume 13 (2007)
-
Volume 12 (2006)
-
Volume 11 (2005)
-
Volume 10 (2004)
-
Volume 9 (2003)
-
Volume 8 (2002)
-
Volume 7 (2001)
-
Volume 6 (2000)
Most Read This Month
Article
content/journals/cpd
Journal
10
5
false
en
